Cyclacel Pharmaceuticals Inc (CYCC)

Pre market volume ramping up. Treasury allocation approval news today?

The share price on 7/4 was around 22 cents at the close. Your chart has been adjusted in its entirety to reflect accurate ups and downs. The # of holders wouldn't have been affected by the split, unless they sold upon gaining news of it (like I did), they just each own less.

Seems to me the price should have shot up to 45 on July 7 with the RS and why did it take so long to kick and now is only 23. Don't think I've ever seen anything like this before. Is it because of the small number of stock holders?

Due to the 1 for 15 R/S a few weeks ago, the shares outstanding has been reduced to 1.5 mil, with around 65% held by insiders. So it isn't taking much to move this one up and down. Between that in institutional holding, the float is now only around 140k shares.

what the deal with volatility ? company said no material change ... at this price then seems way undervalued ? new to this stock just came across due to volatility

Crazy ride today, from four to nearly twenty bucks, 10 minute halts, up, down... Now, after hours back down to under11, and falling. See ya tomorrow. I got in and out today and did ok, but had i been on the ball this morning (I slept in and missed the open) I could've 8xed what I made.

Congrats to those patient shareholders who took the risk.

Talk about an explosion... and no comments? Circuit breakers every minute.

$.32 to $.40 in the last 12 minutes.

Somethings brewing. Price spiking on high volume.

I agree.

CYCC POST RS BEAT DOWN...NOW TIME TO POP

invested in cycc many years ago. no investment has been worse. God knows what they've done except lined
the pockets of a few people. leaving Jersey for summatra seems comically right for this joke company.
my considerable original investment, I could just barely buy a candy bar for what it is worth now. I mean
that literally...

CYCC................................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

CYCC....................................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

David Lazer bought this ticker! When I used to trade otc I would play his takeovers of dead tickers,made good $,I can’t imagine he would not run this up huge

Bought 17k @ .2592

CYCC..................................https://stockcharts.com/h-sc/ui?s=CYCC
&p=W&b=5&g=0&id=p86431144783

CYCC.........................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

CYCC; Mr. David-Lazar-Beam holding up pretty good here!!

CYCC: I too saw that earlier --- the legendary DAVID L.!!! (But, is that enough to rocket this puppy???)

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar $CYCC https://t.co/3qxrEs8xCP— Life Science Report (@lifesciencerpt) January 3, 2025

$CYCC pic.twitter.com/9uAcewGWyH— THE FINAL COUNTDOWN (@THIS_TIME_X) January 3, 2025

David Lazar buys stock 

cycc...........................https://stockcharts.com/h-sc/ui?&s=cycc&id=p80904663129&listNum=4&a=1431976465

cycc.....https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

CYCC  .54 + 30% November 12 2024 - 4:45PM


Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update.“We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”), in Barcelona, Spain. The patients were enrolled in the biomarker-enriched, Cohort 8 of the study and were preselected for CDKN2A and/or CDKN2B abnormalities,” said Spiro Rombotis, President and Chief Executive Officer. “Nasdaq has granted the Company an extension until December 24, 2024, to regain compliance with Nasdaq’s minimum stockholders’ equity requirement and we continue to pursue opportunities to obtain additional funding for our programs. If we do not secure such additional funding in an amount that allows us to meet or exceed Nasdaq’s minimum stockholders’ equity requirement, our securities will be delisted from Nasdaq.”Financial HighlightsAs of September 30, 2024, cash equivalents totaled $3.0 million, compared to $3.4 million as of December 31, 2023. Net cash used in operating activities was $6.6 million for the nine months ended September 30, 2024 compared to $12.2 million for the same period of 2023. The Company estimates that its available cash will fund currently planned programs into the fourth quarter of 2024.Although the Company has made substantial reductions in its expenses, there remains substantial doubt about our ability to continue as a going concern. We are currently investigating ways to raise additional capital through private equity financing or by entering into a strategic transaction. In the event that we are not able to secure such additional funding, we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy. In such events, our stockholders may lose their entire investment in the Company.Research and development (R&D) expenses were $1.0 million for the three months ended September 30, 2024, as compared to $5.2 million for the same period in 2023. R&D expenses relating to fadraciclib were $0.9 million for the three months ended September 30, 2024, as compared to $3.6 million for the same period in 2023 due to manufacturing costs not recurring in 2024. R&D expenses related to plogosertib were $0.1 million for the three months ended September 30, 2024, as compared to $1.5 million for the same period in 2023 also due to manufacturing costs not recurring in 2024.General and administrative expenses for the three months ended September 30, 2024 were $1.2 million, as compared to $1.6 million for the same period in 2023 due largely to reduction in stock compensation costs. Total other income, net, for the three months ended September 30, 2024 was $10,000 compared to an income of $145,000 for the same period of the previous year.United Kingdom research & development tax credits for the three months ended September 30, 2024 were $0.2 million compared to $0.7 million for the same period of the previous year. Research & development tax credits are directly correlated to qualifying research and development expenditure.Net loss for the three months ended September 30, 2024 was $2.0 million, compared to $6.0 million for the same period in 2023.

CYCC......................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

1.70 + 18% float small but ofdering comes at any time with undisclosed price 
Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterationsAbstract Number:59Session:Molecular Targeted AgentsDate/Time:12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23, 2024  

CYCC...............................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

CYCC......................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

CYCC new 52 low

CYCC new 52 week low

CYCC under $2

Low $2s added $2.16- $2.22…BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster here.

“We are excited to report data with fadraciclib monotherapy from the entire Phase 1 population at ASCO. Clinical benefit was observed in heavily pretreated patients with several tumor types, including endometrial, lung, ovarian, pancreatic cancer, and T-cell lymphoma,” said Spiro Rombotis, President and Chief Executive officer. “Retrospective analysis suggests that this activity may be associated in part with alterations in certain tumor suppressor genes forming a hypothesis which we are testing in the ongoing Phase 2 part of the study. We look forward to reporting initial proof of concept data in the second half of 2024.”

“We are encouraged about the early safety and efficacy results of our novel therapeutic candidate fadraciclib. We are continuing fadraciclib’s development in the proof of concept part of the 065-101 study, initially in patients prospectively selected for CDKN2A/CDKN2B alterations, followed by patients with T-cell lymphoma,” added Brian Schwartz, M.D., interim Chief Medical Officer.

New clinical, PK and PD data were presented at ASCO from the fully enrolled, Phase 1, dose escalation part of the CYC065-101 study of fadraciclib as monotherapy (n=47). The patients were heavily pretreated, having received a median of four prior lines of therapy.

Fadraciclib was generally well tolerated with good compliance between dose levels 1 and 5. The most common treatment related adverse events reported were nausea (66.0%), vomiting (46.8%), diarrhea (31.9%) fatigue (25.5%), and hyperglycemia (21.3%). A total of 25 drug-related SAEs were reported in 8 patients, with most common being hyperglycemia (n=4), platelet count decrease (n=3), and accidental overdose (n=3).

There were no drug-related SAEs at dose level 5 (100 mg bid, 5 days a week, for 4/4 weeks) which was selected for the Phase 2 proof of concept part of the 065-101 study. PKs were dose-proportional and exceeded the preclinical efficacy targets for both CDK2 and CDK9. PDs evaluated in peripheral blood showed suppression of CDKN2A/B by four hours post treatment in most patients who received 100 mg bid or higher.

A total of 34 patients had measurable target lesions at baseline. Two partial responses were reported in patients with T-cell lymphoma, one of whom had CDKN2A loss. A squamous non-small cell lung (NSCLC) cancer patient with CDKN2A and CDKN2B loss achieved 22% reduction in tumor burden at 4 weeks per RECIST 1.1 criteria. In addition, clinical benefit was reported in two patients with endometrial cancer, and one each with ovarian and pancreatic cancers.

The proof of concept part of the study is now enrolling patients with CDKN2A/B loss or T-cell lymphoma.

Details of the presentations are as follows:

Title: A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma

Abstract No.
for Publication: 3125

Session Title:
Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Date and Time:
June 1, 2024, 9:00 AM - 12:00 PM CDT

About Cyclin-Dependent Kinases and Fadraciclib
Cyclin-dependent kinases (CDKs) are critical for cell cycle control and transcriptional regulation. Dysregulated CDKs have been linked to the cancer hallmarks of uncontrolled proliferation and increased cancer cell survival. Fadraciclib is a highly selective, potent, orally and intravenously available, next generation inhibitor of CDK2 and CDK9. By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death through anaphase catastrophe of cancer cells at sub-micromolar concentrations.

To date single agent activity, including CR, PR and SD, has been observed in patients with advanced endometrial, squamous non-small cell lung, ovarian and pancreatic cancers and also T-cell lymphoma. In an earlier Phase 1 study of intravenous (IV) fadraciclib, a heavily pretreated endometrial cancer patient with CDKN2A, CDKN2B and MTAP loss achieved confirmed CR and remained on treatment for approximately three years.

065-101 Study of Oral Fadraciclib

Oral fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; NCT#04983810). A total of 47 patients have been treated as monotherapy in this ongoing study. The study is enrolling unselected, all comer patients with advanced solid tumors and lymphoma.

The proof of concept part of the 065-101 study is designed to further evaluate fadra safety and efficacy in up to 8 cohorts defined by histology and/or NGS. The study is currently enrolling the biomarker cohort for patients prospectively selected for CDKN2A/CDKN2B alterations and the T-cell lymphoma cohort. The study is powered to demonstrate response in the molecular subtype suggested by the Phase 1 data and others that may be sensitive.

CDKN2A, CDKN2B deletions

CDKN2A gene deletions occur in over 10% of several solid tumors, including glioma, head and neck, pancreatic, esophageal, lung (incl. squamous), bladder, hepatobiliary, breast, melanoma, sarcoma, and others. CDKN2A deletions have been reported in 46% of patients with PTCL-NOS, a subtype of lymphoma. CDKN2B deletions occur in over 10% of several solid tumors, including bladder, glioma, lung (incl. squamous), head and neck, pancreatic, melanoma, esophageal, sarcoma, hepatobiliary, breast, ovarian and others.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.

Next runner 1.93 stop loss set. 1m float news coming. Heard it first here in action news lol…

This has been a good :"Trading Stock" will look for reentry on Monday dependent on volume levels.

HOlding it's own, well over 10,000 trades per day NOW, and $MILLIONs in dollars being traded, folks are watching , chart indicators are strong.

Lol

$CYCC Hitting the Scanners today for sure . 135,598 Trades, 21,22,265 in traded Volume , PLUS over $ 42 MILLION dollars in traded volume .
--
News out today
https://www.otcmarkets.com/stock/CYCC/news

Like there style lol.. 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.36 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 2, 2024, subject to the satisfaction of customary closing conditions.

And……

they just announced one

https://twitter.com/Cbmcgee2/status/1783238416601137262/photo/1

No offering…The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.

The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.

What happened? I spent the afternoon posting new highs and lows

What leaked

CYCC under $2

What I miss?

CYCC 10Q due 3/19

while s. robotis has certainly got to be in the running for longest serving, worst performing CEO of any American company
in history, one has to admire that decade after decade he is able to draw a sizeable paycheck, while keeping his
handpicked and doubtlessly corrupt bod in his back pocket. he could teach a valuable course at any business school.
what a great subject for a great novel cycc and it's unapologetic, feckless leader would make.
go Spiro go--and you know he will do just that!

CYCC new 52 week low